Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients

Future Oncology

Volumn 11, Issue 21, 2015, Pages 2881-2891

  Conteduca, Vincenza ^a   Caffo, Orazio ^b   Fratino, Lucia ^c   Lo Re, Giovanni ^d   Basso, Umberto ^e   D'Angelo, Alessandro ^f   Donini, Maddalena ^g   Verderame, Francesco ^h   Ratta, Raffaele ⁱ   Procopio, Giuseppe ^j   Campadelli, Enrico ^k   Massari, Francesco ^l   Gasparro, Donatello ^m   Ermacora, Paola ⁿ   Messina, Caterina ^o   Giordano, Monica ^p   Alesini, Daniele ^q   Zagonel, Vittorina ^e   Veccia, Antonello ^b   Lolli, Cristian ^a   Maines, Francesca ^b   De Giorgi, Ugo ^a   more..

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d Santa Maria Degli Angeli Community Hospital   (Italy)

^e VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^f San Vincenzo Hospital   (Italy)

^g CREMONA HOSPITAL   (Italy)

^h Azienda Ospedaliera Villa Sofia C T O   (Italy)

ⁱ UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^j NATIONAL CANCER INSTITUTE   (Italy)

^k Civil Hospital   (Italy)

^l INSTITUT GUSTAVE ROUSSY   (France)

^m UNIVERSITY HOSPITAL OF PARMA   (Italy)

ⁿ UNIVERSITY HOSPITAL OF UDINE   (Italy)

^o Pope John XXIII Hospital   (Italy)

^p SANT ANNA HOSPITAL   (Italy)

^q SAPIENZA UNIVERSITY OF ROME   (Italy)

more..

Author keywords

abiraterone acetate; castration resistant prostate cancer; liver; survival; visceral metastases

Indexed keywords

ABIRATERONE; DOCETAXEL; PREDNISONE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAXOID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LIVER METASTASIS; LUNG DISEASE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; VISCERAL METASTASIS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; VISCERA;

AGED; AGED, 80 AND OVER; ANDROSTENES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; VISCERA;

EID: 84946236823     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.158     Document Type: Article

References (38)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 65(1), 5-29 (2015).
2. Heidenreich A, Bastian PJ, Bellmunt J et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration resistant prostate cancer. Eur. Urol. 65(2), 467-479 (2014).
3. Bourlon MT, Flaig TW. Visceral metastases in prostate cancer: an underestimated and understudied group. Oncology (Williston Park) 28(11), 980-986 (2014).
4. Conteduca V, Aieta M, Amadori D, De Giorgi U. Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies. Crit. Rev. Oncol. Hematol. 92(1), 11-24 (2014).
5. Beltran H, Tomlins S, Aparicio A et al. Aggressive variants of castration-resistant prostate cancer. Clin. Cancer Res. 20(11), 2846-2850 (2014).
6. Pouessel D, Gallet B, Bibeau F et al. Liver metastases in prostate carcinoma: clinical characteristics and outcome. BJU Int. 99(4), 807-811 (2007).
7. Pezaro CJ, Omlin A, Lorente D et al. Visceral disease in castration-resistant prostate cancer. Eur. Urol. 65(2), 270-273 (2014).
8. De Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747), 1147-1154 (2010).
9. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187-1197 (2012).
10. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 513-1520 (2004).
11. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26(2), 242-245 (2008).
12. Small EJ, Halabi S, Dawson NA et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgenindependent prostate cancer patients: a Phase III trial (CALGB 9583). J. Clin. Oncol. 22(6), 1025-1033 (2004).
13. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502-1512 (2004).
14. Goodman OB, Flaig TW, Molina A et al. Exploratory analysis of the visceral disease subgroup in a Phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 17(1), 34-39 (2014).
15. Bubendorf L, Schopfer A, Wagner U et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31(5), 578-583 (2000).
16. Shah RB, Mehra R, Chinnaiyan AM et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 64(24), 9209-2916 (2004).
17. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl J. Med. 364(21), 1995-2005 (2011).
18. Fizazi K, Scher HI, Molina A et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled Phase 3 study. Lancet Oncol. 13(10), 983-992 (2012).
19. Smaletz O, Scher HI, Small EJ et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J. Clin. Oncol. 20(19), 3972-3982 (2002).
20. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 21(7), 1232-1237 (2003).
21. Armstrong AJ, Garrett-Mayer ES, Yang YC et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin. Cancer Res. 13(21), 6396-6403 (2007).
22. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin. Cancer Res. 16(1), 203-211 (2010).
23. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the PSA Working Group. J. Clin. Oncol. 17(11), 3461-3467 (1999).
24. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26(7), 1148-1159 (2008).
25. Caffo O, De Giorgi U, Fratino L et al. Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian named patient programme. BJU Int. 115(5), 764-771 (2015).
26. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228-247 (2009).
27. Loriot Y, Fizazi K, De Bono JS, Forer D, Hirmand M, Scher HI. Outcomes in patients with liver or lung metastatic castration resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: results from the Phase III AFFIRM trial. Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 31 May-4 June 2013 (Abstract 5065).
28. Kelly WK, Halabi S, Carducci M et al. Randomized, double-blind, placebocontrolled Phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J. Clin. Oncol. 30(13), 1534-1540 (2012).
29. Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur. Urol. 65(1), 3-6 (2014).
30. Sella A, Konichezky M, Flex D et al. Low PSA metastatic androgen-independent prostate cancer. Eur. Urol. 38, 250-254 (2000).
31. Drake CG. Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'? Oncology (Williston Park) 28(11), 974-980 (2014).
32. Kim JW, Bilusic M, Plimack ER. Mechanisms of immunotherapy resistance in mCRPC: identifying the enemy on the visceral metastatic battlefield. Oncology (Williston Park) 28(11), 986-090 (2014).
33. Halabi S, Lin CY, Kelly WK et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 32(7), 671-677 (2014).
34. Haffner MC, Mosbruger T, Esopi DM et al. Tracking the clonal origin of lethal prostate cancer. J. Clin. Invest. 123, 4918-4922 (2013).
35. Carreira S, Romanel A, Goodall J et al. Tumor clone dynamics in lethal prostate cancer. Sci. Transl. Med. 6(254), 254ra125 (2014).
36. Robinson D, Van Allen EM, Wu YM et al. Integrative clinical genomics of advanced prostate cancer. Cell 161(5), 1215-1228 (2015).
37. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32(6), 579-786 (2014).
38. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11(6), 426-437 (2011).